For the first time, researchers at Northwestern University's Feinberg School of Medicine have identified how a single gene called aromatase (CYP19A1) triggers a chain reaction in the brain that ...
Kisqali combined with an aromatase inhibitor improved iDFS in hormone receptor-positive, HER2-negative early breast cancer, with a 30% risk reduction in DDFS and distant recurrence-free survival. The ...
An updated joint position statement on the management of aromatase inhibitor-associated bone loss (AIBL) addresses the heightened fracture risk in women undergoing endocrine therapy for ...
For postmenopausal women with hormone-receptor–positive breast cancer, the most effective duration for adjuvant therapy with an aromatase inhibitor remains unclear. In this prospective, phase 3 trial, ...
Treatment with an aromatase inhibitor improves outcomes at 10 years compared to treatment with a SERM in HR+, HER2+ early breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback